Paragon Private Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,965
Closed -$206K 195
2025
Q1
$206K Sell
2,965
-690
-19% -$57K 0.1% 178
2024
Q4
$314K Sell
3,655
-552
-13% -$59.7K 0.15% 132
2024
Q3
$501K Buy
4,207
+37
+0.9% +$4.93K 0.25% 103
2024
Q2
$595K Buy
4,170
+1,096
+36% +$145K 0.34% 83
2024
Q1
$395K Buy
3,074
+492
+19% +$58.6K 0.23% 104
2023
Q4
$267K Buy
2,582
+126
+5% +$12.5K 0.19% 114
2023
Q3
$223K Buy
+2,456
New +$216K 0.18% 115

Other funds holding NVO

Paragon Private Wealth Management's NVO Position: Q2 2025 in Review

Paragon Private Wealth Management sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 2,965 shares — an estimated $206K sold.

Paragon Private Wealth Management first reported a position in NVO in Q3 2023 and held it in 7 quarters. The position peaked at $595K in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Paragon Private Wealth Management reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Paragon Private Wealth Management sold 2,965 Novo Nordisk shares in Q2 2025, an estimated $206K.
  • Paragon Private Wealth Management first reported a position in Novo Nordisk in Q3 2023 and held it in 7 quarters.
  • Paragon Private Wealth Management's Novo Nordisk position peaked at $595K in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Paragon Private Wealth Management's 13F filing for Q2 2025, filed 14 Aug 2025.